Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Novartis to take over MorphoSys in EUR 2.7bn deal, shares jump
(Sharecast News) - Shares in German oncology biopharmaceutical specialist MorphoSys were surging on Tuesday morning, after Swiss pharma giant Novartis announced a deal to acquire it overnight. Novartis said the acquisition agreement, valued at €2.7bn in cash or €68 per share, included two key assets - pelabresib, a late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumours or lymphomas.
It said pelabresib had shown promise as a potential first-line treatment option for MF patients when administered in combination with ruxolitinib.
In a phase three study, it successfully met its primary endpoint of spleen volume reduction and demonstrated positive trends in symptom improvement, all while maintaining a well-tolerated safety profile.
Regulatory filing with the US FDA for pelabresib in MF was planned for the second half of 2024.
Tulmimetostat was meanwhile described as a compound designed to inhibit the function of EZH2 and EZH1 proteins, which was being investigated for various solid tumours and lymphomas in a phase one and two trial.
The acquisition had received unanimous approval from both the Novartis and MorphoSys boards, and was now subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals.
It was expected to conclude in the first half of this year.
"We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer," said Novartis president of development and chief medical officer Shreeram Aradhye.
"With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise.
"Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realise the full impact and value of their investigational medicines for patients with unmet needs."
At 1055 CET (0955 GMT), shares in MorphoSys were up 13.94% in Frankfurt at €65.38, while Novartis was down 0.48% in Zurich at CHF 89.93.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.